查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372869

洛沙坦市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按來源、形式、按應用、地區和競爭細分

Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Source, By Form, By Application, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球氯沙坦市場價值為 16.4 億美元，預計在預測期內將出現顯著成長，預計到 2028 年年複合成長率 (CAGR) 為 4.89%。

氯沙坦是一種主要用於治療高血壓和特定心臟病的藥物。它屬於血管張力素 II 受體阻斷劑 (ARB) 藥物類別。氯沙坦透過舒張血管發揮作用，有效降低血壓並促進血液循環。

氯沙坦的醫藥市場包括製藥公司生產、分銷和銷售氯沙坦片劑或膠囊。此外，該市場可能包括氯沙坦的各種學名藥，隨著品牌藥物的專利到期而上市。氯沙坦不僅用於治療高血壓，還可以用於治療心臟衰竭等疾病，並降低高血壓和心臟擴大患者中風的風險。

市場概況
預測期 2024-2028
2022 年市場規模 16.4億美元
2028 年市場規模 21.9億美元
2023-2028 年年複合成長率 4.89%
成長最快的細分市場 合約製造組織
最大的市場 北美洲

主要市場促進因素

高血壓盛行率不斷上升

高血壓（高血壓）是全世界常見的健康狀況。隨著全球人口老化以及不良飲食和久坐行為等生活方式因素的持續存在，高血壓的盛行率趨於增加。這推動了對氯沙坦等抗高血壓藥物的需求。現代久坐的生活方式，加上高鹽和加工食品的飲食，會導致血壓水平升高。不良的飲食選擇、缺乏運動和肥胖是已知的高血壓危險因子。隨著這些生活習慣的持續存在，越來越多的人被診斷出患有高血壓，導致對氯沙坦等用於控制和管理病情的藥物的需求增加。

老年人口增加

老年人口的增加是氯沙坦需求增加的重要推動因素，氯沙坦是一種用於治療高血壓和某些心臟疾病的藥物。這種人口結構的變化正在重塑醫療保健的優先事項，並加劇了對高血壓等與年齡相關的健康問題的有效治療的需求。隨著個體年齡的成長，患高血壓的風險大大增加。由於血管彈性和荷爾蒙調節的變化，血壓往往會隨著年齡的成長而升高。因此，不斷成長的老年人口導致高血壓盛行率升高，需要氯沙坦等藥物干涉措施來維持最佳血壓水平。

氯沙坦特別適合老年人。其作為血管緊張素 II 受體阻斷劑 (ARB) 的作用機制使其能夠放鬆血管、減少動脈僵硬度並有效降低血壓，所有這些對於控制老年人高血壓至關重要。此外，氯沙坦的安全性和相對輕微的副作用使其成為可能需要多種藥物來治療各種與年齡相關的疾病的老年人的首選。

醫療保健服務的改善以及對與不受控制的高血壓相關的健康風險的認知的提高，使得老年人群能夠得到更早的診斷和治療。隨著醫療保健提供者強調血壓控制的重要性，氯沙坦已成為老年人高血壓醫療管理的主要藥物。預計未來幾年人口老化趨勢將持續，65 歲以上人口比例不斷增加。因此，隨著醫療保健系統滿足該族群的獨特醫療保健需求，對氯沙坦和其他抗高血壓藥物的需求預計將上升。氯沙坦在維持老年人心血管健康和生活品質方面的作用凸顯了其在滿足老齡化世界的醫療保健需求方面的重要性。

提高臨床療效

氯沙坦和其他血管張力素 II 受體阻斷劑 (ARB) 已證明其在降低血壓和降低心血管事件風險方面的有效性。正面的臨床結果和良好的安全性可以促使醫療保健提供者開出氯沙坦處方。氯沙坦不斷提高的臨床療效是其在醫療保健領域需求不斷成長的關鍵驅動力。氯沙坦是一種血管緊張素 II 受體阻斷劑 (ARB)，因其在控制高血壓和某些心臟病方面的有效性而受到關注，使其成為醫療保健提供者和患者的首選。

此外，氯沙坦已顯示出降低高血壓患者心血管事件風險的功效。眾所周知，它可以透過減少心臟壓力和改善血流量對心臟健康產生積極影響。它對心血管系統的保護作用使其成為預防心臟病、中風和其他心血管併發症的寶貴工具，這對醫療保健提供者和患者來說都是一個重要的考慮因素。氯沙坦在降低血壓、降低心血管風險方面不斷增強的臨床療效及其良好的耐受性使其成為醫療保健提供者和患者的首選。這項臨床成功推動了氯沙坦治療高血壓和相關心血管疾病的需求不斷成長。

專利到期和學名藥競爭

氯沙坦品牌藥物的專利到期後，學名藥可以進入市場。學名藥競爭通常會導致藥品價格下降，使更廣泛的人群更容易獲得藥物。氯沙坦等品牌藥物的專利到期導致學名藥的推出，從而顯著增加了對氯沙坦的需求。學名藥通常比品牌藥便宜。隨著氯沙坦的專利到期，學名藥製造商能夠以較低的成本生產和銷售其版本的藥物。這種負擔能力使更多的患者可以使用氯沙坦，從而增加了那些以前可能因品牌產品的成本而望而卻步的人的需求。

隨著氯沙坦學名藥的出現，更多的醫療保健提供者可能傾向於將其作為患者的經濟有效的選擇。氯沙坦的使用範圍擴大使更多的人受益於其抗高血壓特性，從而增加了需求。隨著學名藥氯沙坦在市場上變得更加普遍和可信，患者和醫療保健專業人員都更加意識到其可用性和功效。這種認知的提高導致了更多的處方和對氯沙坦的更高的需求。

主要市場挑戰

副作用和耐受性

氯沙坦的副作用和耐受性可能是阻礙某些人對其需求和使用的重要因素。雖然許多患者通常對氯沙坦的耐受性良好，但有些患者可能會出現副作用，導致停藥或不願使用該藥物。耐受性也因人而異。有些患者可能發現氯沙坦比其他抗高血壓藥物的耐受性更好，而其他患者可能有不同的反應。個體因素，例如年齡、潛在疾病和合併用藥，可能會影響一個人對氯沙坦的耐受程度。雖然氯沙坦是一種有效的抗高血壓藥物，但其副​​作用和耐受性問題可能會阻礙某些人對其的需求和使用。患者教育、與醫療保健提供者的開放溝通以及個人化治療計劃對於解決這些問題並確保患者接受適當的高血壓治療同時最大限度地減少副作用至關重要。

替代藥物

有多種類型的抗高血壓藥物可供選擇，醫療保健提供者可能會根據患者的個別特徵和偏好開出替代藥物。合併症、禁忌症和患者反應等因素可能會影響藥物的選擇，在某些情況下可能會減少對氯沙坦的需求。患者對藥物的偏好和信念可能會影響他們服用氯沙坦或其他藥物的意願。有些患者可能更喜歡自然療法、整體療法或替代療法而不是藥物干涉，從而減少了對氯沙坦的需求。醫療保健差異，包括獲得醫療保健服務和藥物的機會不平等，可能會限制服務不足的人口對氯沙坦的需求。醫療保健取得方面的不平等可能會阻礙個人接受適當的診斷和治療。

有特定醫療狀況或禁忌症的患者可能不適合服用氯沙坦。例如，患有某些腎臟疾病或對氯沙坦過敏的人可能會被開出替代藥物。在某些情況下，醫療保健提供者會開出包含不只一種抗高血壓藥物的聯合療法。這些組合可以包括不同類別的藥物或同一類別內的多種藥物。聯合治療的選擇取決於患者獨特的醫療需求和最佳血壓控制的願望。

主要市場趨勢

遠距醫療和遠端監控

遠距醫療和遠端監控技術的採用擴大了醫療保健服務的範圍。這些技術使醫療保健提供者能夠遠端監測患者的血壓並根據需要調整治療計劃，從而可能增加對氯沙坦等藥物的需求。遠距醫療允許患者遠距諮詢醫療保健提供者，消除地理障礙，使個人更容易獲得及時的醫療照護。這種增強的可及性可以導致更頻繁的血壓監測和更好的藥物管理。患者可以在舒適的家中與醫療保健專業人員討論他們的治療計劃，包括氯沙坦的使用。

遠端監測設備，例如家用血壓計和穿戴式設備，使患者能夠持續追蹤自己的血壓水平。這些設備可以直接將資料傳輸給醫療保健提供者，以便在必要時進行即時監控和調整治療計劃。透過持續監測可以更準確地評估氯沙坦的有效性。

個人化醫療

醫療保健技術和基因研究的進步正在帶來更個人化的治療方法。考慮個人基因組成和獨特健康特徵的客製化治療計劃可能會增加對氯沙坦等藥物的需求，這可以成為個人化高血壓管理策略的一部分。個人化醫療通常從基因分析開始。透過分析個人的基因組成，醫療保健提供者可以識別影響其對藥物反應的基因變異。對於氯沙坦，基因檢測可以幫助確定患者是否更有可能對該藥物產生良好反應，或者替代療法是否可能更合適。這種精確的方法確保將氯沙坦開給最有可能從中受益的人，從而增加了合適候選人的需求。

個人化醫療允許根據遺傳和個別患者資料微調藥物劑量。對於氯沙坦來說，這意味著醫療保健提供者可以調整劑量，以實現每位患者的最佳血壓控制。避免過度或用藥不足可以改善患者的治療效果並減少潛在的副作用，從而提高患者的滿意度和對氯沙坦的需求。

細分市場洞察

形成洞察

根據形式，市場分為片劑和粉末。片劑形式的氯沙坦的需求高於其他形式（例如粉劑）的需求。片劑易於操作和吞嚥，使其成為大多數患者（包括老年人和吞嚥困難患者）的便捷選擇。片劑經過預先測量並提供標準化劑量，確保準確且一致的用藥。氯沙坦片劑通常採用泡罩包裝或瓶子包裝，以便於安全儲存和運輸。患者和醫療保健提供者通常更熟悉片劑藥物，這有助於其受歡迎。

應用洞察

根據應用領域，市場分為高血壓、中風、糖尿病腎病變等。高血壓細分市場佔據主導地位，因為氯沙坦主要用於治療高血壓（俗稱高血壓）。高血壓是一個普遍存在的健康問題，影響著全球很大一部分人口。據估計，全世界有超過十億人患有高血壓。這種高盛行率確保了對氯沙坦等抗高血壓藥物的持續和大量需求。近年來，人們一致努力提高人們對高血壓的認知並推廣定期血壓監測。因此，越來越多的人被診斷出患有高血壓，導致對有效治療的需求增加。隨著年齡的成長，高血壓往往變得更加普遍。隨著全球人口老化，越來越多的人面臨高血壓的風險，進一步推動了對抗高血壓藥物的需求。

區域洞察

北美，包括美國和加拿大，對氯沙坦等抗高血壓藥物的需求量大。該地區人口老化嚴重，高血壓是常見的健康問題。人們對心血管健康的認知的提高和獲得醫療保健服務的機會的增加導致了對這些藥物的強勁需求。美國和加拿大擁有完善的醫療保健系統和基礎設施。獲得醫療保健服務（包括定期檢查和診斷測試）的情況相對普遍。這有助於高血壓的診斷和管理，並增加了對抗高血壓藥物的需求。北美非常重視健康意識和預防。醫療保健組織、政府機構和非營利組織所進行的教育活動和措施提高了人們對包括高血壓在內的心血管危險因子的認知。這種意識的提高鼓勵個人尋求醫療護理並遵守規定的治療計劃，包括使用氯沙坦等藥物。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源（合約製造組織、內部）
    • 按劑型（錠劑、粉末）
    • 按應用（高血壓、中風、糖尿病腎病變、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源
    • 按形式
    • 按應用
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源
    • 按形式
    • 按應用
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源
    • 按形式
    • 按應用
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源
    • 按形式
    • 按應用
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲氯沙坦市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按來源
    • 按形式
    • 按應用
    • 按國家/地區
  • MEA：國家分析
    • 南非 氯沙坦
    • 沙烏地阿拉伯 洛沙坦
    • 阿拉伯聯合大公國 洛沙坦

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球氯沙坦市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Novartis International AG
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceuticals Industries Ltd.
    • Aurobindo Pharma Ltd.
    • Torrent Pharmaceutical Ltd.
    • Lupin Ltd.

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 7269

The Global Losartan Market, valued at USD 1.64 Billion in 2022, is poised for remarkable growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 4.89% through 2028.

Losartan is a medication primarily prescribed for the treatment of high blood pressure (hypertension) and specific heart conditions. It falls under the category of drugs known as angiotensin II receptor blockers (ARBs). Losartan operates by relaxing blood vessels, effectively reducing blood pressure and enhancing blood circulation.

The pharmaceutical market for Losartan encompasses the production, distribution, and sale of Losartan tablets or capsules by pharmaceutical companies. Additionally, this market may include various generic versions of Losartan that become available as the patent for the brand-name medication expires. Losartan is not only used to manage hypertension but may also be employed for treating conditions like heart failure and reducing the risk of stroke in individuals with hypertension and an enlarged heart.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.64 Billion
Market Size 2028USD 2.19 Billion
CAGR 2023-20284.89%
Fastest Growing SegmentContract Manufacturing Organizations
Largest MarketNorth America

Key Market Drivers

Growing Prevalence of Hypertension

High blood pressure (hypertension) is a common health condition worldwide. As the global population ages and lifestyle factors such as poor diet and sedentary behavior continue, the prevalence of hypertension tends to increase. This drives the demand for antihypertensive medications like Losartan. Modern sedentary lifestyles, coupled with diets high in salt and processed foods, contribute to rising blood pressure levels. Poor dietary choices, lack of exercise, and obesity are known risk factors for hypertension. As these lifestyle habits persist, more people are diagnosed with high blood pressure, leading to an increased demand for medications like Losartan to control and manage their condition.

Increased awareness and healthcare accessibility have led to earlier diagnosis and treatment of hypertension. Health campaigns and routine health check-ups have heightened awareness of the risks associated with uncontrolled blood pressure, prompting individuals to seek medical intervention. Losartan's efficacy in reducing blood pressure and its tolerability have made it a preferred choice among healthcare providers, further driving its demand. The availability of generic versions of Losartan has made hypertension management more affordable for patients, increasing its accessibility to a broader population. This affordability factor has a significant impact on the demand for Losartan, especially in regions with limited healthcare resources.

Rising Geriatric Population

The rising geriatric population is a significant driver of the increasing demand for Losartan, a medication used to manage hypertension and certain heart conditions. This demographic shift is reshaping healthcare priorities and intensifying the need for effective treatments for age-related health issues, such as high blood pressure. As individuals age, the risk of developing hypertension rises substantially. Blood pressure tends to increase with age due to changes in blood vessel elasticity and hormonal regulation. Consequently, a growing elderly population translates to a higher prevalence of hypertension, necessitating pharmaceutical interventions like Losartan to maintain optimal blood pressure levels.

Losartan is particularly well-suited for older adults. Its mechanism of action as an angiotensin II receptor blocker (ARB) allows it to relax blood vessels, reduce arterial stiffness, and lower blood pressure effectively, all of which are crucial in managing hypertension in the elderly. Additionally, Losartan's safety profile and relatively mild side effects make it a preferred choice for older individuals who may have multiple medications to manage various age-related conditions.

Improved healthcare access and increased awareness of the health risks associated with uncontrolled hypertension have led to earlier diagnosis and treatment in the elderly population. With healthcare providers emphasizing the importance of blood pressure control, Losartan has become a staple in the medical management of hypertension among older adults. The aging population trend is expected to continue in the coming years, with a growing proportion of people over the age of 65. Consequently, the demand for Losartan and other antihypertensive medications is poised to rise as healthcare systems address the unique healthcare needs of this demographic. Losartan's role in maintaining cardiovascular health and quality of life in the elderly population underscores its significance in meeting the healthcare demands of an aging world.

Increasing Clinical Efficacy

Losartan and other angiotensin II receptor blockers (ARBs) have demonstrated their effectiveness in lowering blood pressure and reducing the risk of cardiovascular events. Positive clinical outcomes and a good safety profile can drive healthcare providers to prescribe Losartan. The increasing clinical efficacy of Losartan is a key driver behind its growing demand in the healthcare sector. Losartan, an angiotensin II receptor blocker (ARB), has gained prominence due to its effectiveness in managing hypertension and certain heart conditions, making it a preferred choice for both healthcare providers and patients.

Furthermore, Losartan has shown efficacy in reducing the risk of cardiovascular events in hypertensive individuals. It is known to have a positive impact on cardiac health by decreasing the strain on the heart and improving blood flow. Its protective effects on the cardiovascular system make it a valuable tool in the prevention of heart attacks, strokes, and other cardiovascular complications, which is a critical consideration for healthcare providers and patients alike. The increasing clinical efficacy of Losartan in lowering blood pressure, reducing cardiovascular risks, and its favorable tolerability profile have made it a preferred choice for healthcare providers and patients. This clinical success is a driving force behind the growing demand for Losartan in the treatment of hypertension and related cardiovascular conditions.

Patent Expiration and Generic Competition

The expiration of patents for brand-name Losartan medications allows generic versions to enter the market. Generic competition often leads to lower drug prices, making the medication more accessible to a broader population. The expiration of patents for brand-name medications like Losartan has led to the introduction of generic versions, significantly increasing the demand for Losartan. Generic medications are typically more affordable than their brand-name counterparts. As Losartan's patent expired, generic manufacturers were able to produce and market their versions of the drug at a lower cost. This affordability makes Losartan accessible to a broader population of patients, increasing its demand among those who may have been previously deterred by the cost of the brand-name product.

With the availability of generic Losartan, more healthcare providers may be inclined to prescribe it as a cost-effective option for their patients. This expanded access to Losartan enables a larger number of individuals to benefit from its antihypertensive properties, thus increasing demand. As generic Losartan becomes more prevalent and trusted in the market, patients and healthcare professionals alike become more aware of its availability and efficacy. This increased awareness leads to more prescriptions and higher demand for Losartan.

Key Market Challenges

Side Effects and Tolerability

The side effects and tolerability of Losartan can be a significant factor hindering its demand and use among some individuals. While Losartan is generally well-tolerated by many patients, some may experience side effects that lead to discontinuation or reluctance to use the medication. Tolerability also varies from person to person. Some patients may find Losartan to be better tolerated than other antihypertensive medications, while others may have a different response. Individual factors, such as age, underlying medical conditions, and concomitant medications, can influence how well a person tolerates Losartan. While Losartan is an effective antihypertensive medication, its side effects and tolerability issues can hinder its demand and use among certain individuals. Patient education, open communication with healthcare providers, and personalized treatment plans are essential in addressing these concerns and ensuring that patients receive appropriate treatment for their hypertension while minimizing side effects.

Alternative Medications

There are several classes of antihypertensive medications available, and healthcare providers may prescribe alternative drugs based on individual patient characteristics and preferences. Factors such as comorbidities, contraindications, and patient response can influence the choice of medication, potentially reducing the demand for Losartan in some cases. Patient preferences and beliefs about medications can influence their willingness to take Losartan or other drugs. Some patients may prefer natural remedies, holistic approaches, or alternative therapies over pharmaceutical interventions, reducing the demand for Losartan. Healthcare disparities, including unequal access to healthcare services and medications, can limit the demand for Losartan among underserved populations. Inequities in healthcare access can prevent individuals from receiving appropriate diagnoses and treatments.

Patients with specific medical conditions or contraindications may not be suitable candidates for Losartan. For instance, individuals with certain kidney conditions or allergies to Losartan may be prescribed alternative medications. In some cases, healthcare providers prescribe combination therapies that include more than one type of antihypertensive medication. These combinations can include different classes of drugs or multiple drugs within the same class. The choice of combination therapy depends on the patient's unique medical needs and the desire for optimal blood pressure control.

Key Market Trends

Telehealth and Remote Monitoring

The adoption of telehealth and remote monitoring technologies has expanded access to healthcare services. These technologies allow healthcare providers to monitor patients' blood pressure remotely and adjust treatment plans as needed, potentially increasing the demand for medications like Losartan. Telehealth allows patients to consult with healthcare providers remotely, eliminating geographical barriers and making it easier for individuals to receive timely medical care. This enhanced accessibility can lead to more frequent monitoring of blood pressure and better medication management. Patients can discuss their treatment plans, including the use of Losartan, with healthcare professionals from the comfort of their homes.

Remote monitoring devices, such as home blood pressure monitors and wearable devices, enable patients to track their blood pressure levels consistently. These devices can transmit data directly to healthcare providers, allowing for real-time monitoring and adjustments to treatment plans when necessary. Losartan's effectiveness can be assessed more accurately through continuous monitoring.

Personalized Medicine

Advances in healthcare technology and genetic research are leading to more personalized treatment approaches. Tailored treatment plans that consider an individual's genetic makeup and unique health characteristics may increase the demand for medications like Losartan, which can be part of a personalized hypertension management strategy. Personalized medicine often begins with genetic profiling. By analyzing an individual's genetic makeup, healthcare providers can identify genetic variations that influence their response to medications. For Losartan, genetic testing can help determine whether a patient is more likely to respond favorably to the drug or if alternative treatments might be more appropriate. This precise approach ensures that Losartan is prescribed to those who are most likely to benefit from it, increasing demand among suitable candidates.

Personalized medicine allows for the fine-tuning of medication dosages based on genetic and individual patient data. For Losartan, this means that healthcare providers can adjust the dosage to achieve the optimal blood pressure control for each patient. Avoiding overmedication or undermedication enhances patient outcomes and reduces potential side effects, increasing patient satisfaction and demand for Losartan.

Segmental Insights

Form Insights

Based on the form, the market is segmented into tablet and powder. The demand for Losartan in tablet form is higher than that for other forms, such as powder. Tablets are easy to handle and swallow, making them a convenient choice for most patients, including the elderly and those with swallowing difficulties. Tablets are pre-measured and provide a standardized dosage, ensuring accurate and consistent medication administration. Losartan tablets are typically packaged in blister packs or bottles, making it easy to store and transport them safely. Patients and healthcare providers are generally more familiar with tablet medications, which contributes to their popularity.

Application Insights

Based on the application segment, the market is segmented into hypertension, stroke, diabetic nephropathy, and others. The hypertension segment dominated the market as Losartan is primarily used for the treatment of hypertension, which is commonly known as high blood pressure. Hypertension is a widespread health issue, affecting a substantial portion of the global population. It is estimated that over one billion people worldwide have hypertension. This high prevalence ensures a consistent and substantial demand for antihypertensive medications like Losartan. In recent years, there has been a concerted effort to raise awareness about hypertension and promote regular blood pressure monitoring. As a result, more individuals are being diagnosed with high blood pressure, leading to an increased demand for effective treatments. Hypertension tends to become more prevalent with age. As the global population ages, a larger proportion of individuals are at risk of developing hypertension, further driving the demand for antihypertensive medications.

Regional Insights

North America, including the United States and Canada, has a significant demand for antihypertensive medications like Losartan. The region has a large aging population, and hypertension is a common health issue. Increased awareness of cardiovascular health and access to healthcare services contribute to a robust demand for these medications. The United States and Canada have well-established healthcare systems and infrastructure. Access to healthcare services, including regular check-ups and diagnostic testing, is relatively widespread. This facilitates the diagnosis and management of hypertension and contributes to the demand for antihypertensive medications. There is a strong emphasis on health awareness and prevention in North America. Educational campaigns and initiatives by healthcare organizations, government agencies, and non-profit organizations promote awareness of cardiovascular risk factors, including hypertension. This heightened awareness encourages individuals to seek medical care and adhere to prescribed treatment plans, including the use of medications like Losartan.

Key Market Players

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

Report Scope:

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

  • Contract Manufacturing Organizations
  • In-House

Losartan Market, By Form:

  • Tablet
  • Powder

Losartan Market, By Application:

  • Hypertension
  • Stroke
  • Diabetic Nephropathy
  • Others

Losartan Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations:

  • Global Losartan market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Losartan Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
    • 5.2.2. By Form (Tablet, Powder)
    • 5.2.3. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Losartan Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Form
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Losartan Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Source
        • 6.3.1.2.2. By Form
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Losartan Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Source
        • 6.3.2.2.2. By Form
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Losartan Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Source
        • 6.3.3.2.2. By Form
        • 6.3.3.2.3. By Application

7. Europe Losartan Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Form
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Losartan Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Source
        • 7.3.1.2.2. By Form
        • 7.3.1.2.3. By Application
    • 7.3.2. United Kingdom Losartan Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Source
        • 7.3.2.2.2. By Form
        • 7.3.2.2.3. By Application
    • 7.3.3. Italy Losartan Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Source
        • 7.3.3.2.2. By Form
        • 7.3.3.2.3. By Application
    • 7.3.4. France Losartan Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Source
        • 7.3.4.2.2. By Form
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Losartan Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Source
        • 7.3.5.2.2. By Form
        • 7.3.5.2.3. By Application

8. Asia-Pacific Losartan Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Form
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Losartan Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Source
        • 8.3.1.2.2. By Form
        • 8.3.1.2.3. By Application
    • 8.3.2. India Losartan Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Source
        • 8.3.2.2.2. By Form
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Losartan Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Source
        • 8.3.3.2.2. By Form
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Losartan Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Source
        • 8.3.4.2.2. By Form
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Losartan Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Source
        • 8.3.5.2.2. By Form
        • 8.3.5.2.3. By Application

9. South America Losartan Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Form
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Losartan Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Source
        • 9.3.1.2.2. By Form
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Losartan Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Source
        • 9.3.2.2.2. By Form
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Losartan Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Source
        • 9.3.3.2.2. By Form
        • 9.3.3.2.3. By Application

10. Middle East and Africa Losartan Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Form
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Losartan Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Source
        • 10.3.1.2.2. By Form
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Losartan Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Source
        • 10.3.2.2.2. By Form
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Losartan Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Source
        • 10.3.3.2.2. By Form
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Losartan Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Merck & Co. Inc.
    • 15.5.2. Pfizer Inc.
    • 15.5.3. Teva Pharmaceutical Industries Ltd.
    • 15.5.4. Sanofi S.A.
    • 15.5.5. Novartis International AG
    • 15.5.6. Dr. Reddy's Laboratories Ltd.
    • 15.5.7. Sun Pharmaceuticals Industries Ltd.
    • 15.5.8. Aurobindo Pharma Ltd.
    • 15.5.9. Torrent Pharmaceutical Ltd.
    • 15.5.10. Lupin Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer